Allstate Corp Has $870,000 Stock Position in Hologic, Inc. $HOLX

Key Points

• Allstate Corp increased its stake in Hologic, Inc. by 97.4% during Q1, holding 14,086 shares valued at $870,000.
• Institutional investors own 94.73% of Hologic's stock, with several hedge funds significantly raising their positions in the first quarter.
• Hologic's stock received an upgraded rating from Royal Bank of Canada, increasing its price target from $72 to $87, reflecting positive market sentiment.

Allstate Corp lifted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 97.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,086 shares of the medical equipment provider's stock after acquiring an additional 6,952 shares during the period. Allstate Corp's holdings in Hologic were worth $870,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC grew its stake in shares of Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after acquiring an additional 335 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after acquiring an additional 5,172 shares during the last quarter. Brevan Howard Capital Management LP grew its stake in shares of Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after acquiring an additional 8,960 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in shares of Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after acquiring an additional 528 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its stake in shares of Hologic by 4.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after acquiring an additional 767 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HOLX. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Stephens reduced their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Finally, Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Stock Up 1.6%

Shares of NASDAQ HOLX opened at $68.26 on Monday. The stock has a market cap of $15.18 billion, a PE ratio of 28.32, a PEG ratio of 2.48 and a beta of 0.49. The business has a fifty day moving average of $65.90 and a two-hundred day moving average of $62.40. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business's revenue was up 1.2% on a year-over-year basis. During the same period last year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.